AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15896247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine co-administered with ketoconazole (400 mg/day for 10 days)
Number of subjects: 8
Study 15896247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine carboxylic acid metabolite
Number of subjects: 8
Study 12010667 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UFH (12,500 IU for one week followed by 10,000 IU)
Number of subjects: 60
Study 12010667 — intervention group
Group type: COMPARATOR
Intervention: Low-dose UFH (5,000 IU)
Number of subjects: 60
Study 10333394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation (group I)
Number of subjects: 169
Study 10333394 — intervention group
Group type: COMPARATOR
Intervention: Nonintubation (group II)
Number of subjects: 169
Study 7644088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20-40 mg bid for three weeks
Number of subjects: 19
Study 7644088 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10-20 mg bid for three weeks
Number of subjects: 19
Study 2655462 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of sodium fluoride daily
Number of subjects: 95
Study 2655462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 738077 — intervention group
Group type: EXPERIMENTAL
Intervention: Stomahesive adhesive plaster
Number of subjects: 30
Study 738077 — intervention group
Group type: COMPARATOR
Intervention: Other adhesive plasters
Number of subjects: 30
Study 31820274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine 10 mg twice daily for 12 weeks
Number of subjects: 41
Study 31820274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31486004 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeSource UA-789AC monitor
Number of subjects: 167
Study 31486004 — intervention group
Group type: COMPARATOR
Intervention: mercury sphygmomanometer
Number of subjects: 167
Study 31486004 — intervention group
Group type: EXPERIMENTAL
Intervention: calibrated NYC HANES 2013-2014 blood pressure data
Number of subjects: 167
Study 25787999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild emotional stressor
Number of subjects: 41
Study 25787999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no emotional stressor)
Number of subjects: 41
Study 25787999 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental feeding practices (reward and restriction)
Number of subjects: 41
Study 23500313 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in hemoglobin concentration during hospitalization
Number of subjects: 1969
Study 23500313 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin levels
Number of subjects: 1969
Study 23500313 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose of diuretics
Number of subjects: 1969
Study 23500313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and baseline renal function
Number of subjects: 1969
Study 23500313 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration of renal function
Number of subjects: 1969
Study 23525022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single elbow crutch with conventional exercises for 6 weeks
Number of subjects: 40
Study 23525022 — intervention group
Group type: COMPARATOR
Intervention: Walker with conventional exercises for 6 weeks
Number of subjects: 40
Study 19567768 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with MRKH
Number of subjects: 66
Study 19567768 — intervention group
Group type: COMPARATOR
Intervention: Control group women
Number of subjects: 66
Study 16634952 — intervention group
Group type: EXPERIMENTAL
Intervention: High responders (HR)
Number of subjects: 96
Study 16634952 — intervention group
Group type: EXPERIMENTAL
Intervention: Low responders (LR)
Number of subjects: 96
Study 16634952 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HR and LR
Number of subjects: 96
Study 12632341 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose cisplatin-based chemotherapy (PEB)
Number of subjects: 25
Study 12632341 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin-based chemotherapy (HDPEB)
Number of subjects: 25
Study 12632341 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both groups)
Number of subjects: 25
Study 10784332 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Striper micron finishing system (MFS)
Number of subjects: 80
Study 10784332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof-Lex XT (Sof-Lex)
Number of subjects: 80
Study 10784332 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhance composite finishing and polishing system (Enhance)
Number of subjects: 80
Study 10784332 — intervention group
Group type: EXPERIMENTAL
Intervention: Shofu composite finishing kit (Shofu)
Number of subjects: 80
Study 8769183 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine microemulsion)
Number of subjects: 0
Study 1567489 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic dolorimeter
Number of subjects: 30
Study 1567489 — intervention group
Group type: COMPARATOR
Intervention: Conventional ARA joint tenderness counts
Number of subjects: 30
Study 3893385 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity direct current (LIDC) protocol
Number of subjects: 30
Study 3893385 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound therapy
Number of subjects: 30
Study 31869430 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (GLY)
Number of subjects: 108
Study 31869430 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 108
Study 31869430 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin combination therapy (COMBO)
Number of subjects: 108
Study 31869430 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET) and Glyburide/Metformin combination therapy (COMBO)
Number of subjects: 108
Study 30074649 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based group (intervention)
Number of subjects: 150
Study 27733219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP block with 0.5% ropivacaine 20 ml at 30 minutes before surgery
Number of subjects: 80
Study 27733219 — intervention group
Group type: COMPARATOR
Intervention: TAP sham block with normal saline
Number of subjects: 80
Study 24534763 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa
Number of subjects: 362
Study 24534763 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Number of subjects: 362
Study 24534763 — intervention group
Group type: COMPARATOR
Intervention: Cohort 1a (previously treated with ERT)
Number of subjects: 362
Study 24534763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1b (newly started on ERT)
Number of subjects: 362
Study 24534763 — intervention group
Group type: COMPARATOR
Intervention: Cohort 1c (not initially treated with ERT)
Number of subjects: 362
Study 22435844 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions to associate women with science in Expt 1
Number of subjects: 0
Study 22435844 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions to associate women with superordinate positions in Expt 4
Number of subjects: 0
Study 22435844 — intervention group
Group type: COMPARATOR
Intervention: Egalitarian goal intentions in Expt 2
Number of subjects: 0
Study 22435844 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions in Expt 3
Number of subjects: 0
Study 20642294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 260
Study 18564806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 60
Study 18564806 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 60
Study 15327929 — intervention group
Group type: EXPERIMENTAL
Intervention: Double visual stimuli (white)
Number of subjects: 2
Study 15327929 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic purple stimuli
Number of subjects: 2
Study 15327929 — intervention group
Group type: COMPARATOR
Intervention: Monochromatic red stimuli
Number of subjects: 2
Study 10957661 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous heparin injections (HEP group)
Number of subjects: 48
Study 10957661 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-length sequential EPC device (EPC group)
Number of subjects: 48
Study 10957661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both subcutaneous heparin injections and EPC device (HEP + EPC group)
Number of subjects: 48
Study 9285071 — intervention group
Group type: EXPERIMENTAL
Intervention: B13/L2 supplementation (13 mg beta-carotene, 2 mg lycopene, 5 mg vitamin E, 30 mg vitamin C)
Number of subjects: 20
Study 9285071 — intervention group
Group type: COMPARATOR
Intervention: B3/L3 supplementation (3 mg beta-carotene, 3 mg lycopene, 5 mg vitamin E, 30 mg vitamin C)
Number of subjects: 20
Study 8333483 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 101
Study 8333483 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 101
Study 3553031 — intervention group
Group type: EXPERIMENTAL
Intervention: High-molecular-weight, formalinized allergoid
Number of subjects: 59
Study 3553031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31881459 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal individualized mixed management intervention (4 sessions)
Number of subjects: 182
Study 31881459 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study 29868830 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 823
Study 29868830 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 823
Study 26851201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (1-3mg/24 h)
Number of subjects: 30
Study 26851201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25008439 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% 5-fluorouracil (5-FU)
Number of subjects: 99
Study 25008439 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 99
Study 22710564 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Number of subjects: 148
Study 22710564 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 148
Study 20170481 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable dental prostheses for molar replacement (treatment A)
Number of subjects: 215
Study 20170481 — intervention group
Group type: COMPARATOR
Intervention: Fixed bridges for replacement of all missing anterior and premolar teeth (treatment B)
Number of subjects: 215
Study 20170481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments A and B
Number of subjects: 215
Study 18498925 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib added to gemcitabine treatment regimen for 40% (n=10) of gemcitabine-treated patients for 15.7 weeks of therapy
Number of subjects: 43
Study 18498925 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 43
Study 18498925 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib added to gemcitabine treatment regimen
Number of subjects: 43
Study 15791818 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 15791818 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 15791818 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole vs Tamoxifen
Number of subjects: 0
Study 12525801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention program based on Social Learning Theory emphasizing fruit exposure and positive parent-child feeding strategies
Number of subjects: 9
Study 12525801 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 parent-child pairs who expressed interest but were unable to attend more than one session)
Number of subjects: 9
Study 12525801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention program
Number of subjects: 9
Study 12525801 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study 10813547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid/cross-linked sodium carboxymethyl cellulose system with enteric-coated capsule
Number of subjects: 0
Study 10813547 — intervention group
Group type: COMPARATOR
Intervention: Conventional commercial ursodeoxycholic acid capsules
Number of subjects: 0
Study 10813547 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug/polymer system
Number of subjects: 0
Study 8871751 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 IU/kg)
Number of subjects: 316
Study 8871751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 1502021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day) for 24 weeks
Number of subjects: 615
Study 1502021 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 615
Study 6383692 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naloxone infusion during severe exercise
Number of subjects: 6
Study 6383692 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion during severe exercise
Number of subjects: 6
Study 6383692 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (both mild and severe)
Number of subjects: 6
Study 6383692 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 6
Study 6383692 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 6
Study 31674256 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (CT) group with low-dose dexamethasone (5mg/d) for 5 days
Number of subjects: 121
Study 31674256 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (CT) group
Number of subjects: 121
Study 31674256 — intervention group
Group type: COMPARATOR
Intervention: Medical comprehensive treatment (MCT) group
Number of subjects: 121
Study 31674256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study 30071781 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation (10.6 µm)
Number of subjects: 26
Study 30071781 — intervention group
Group type: COMPARATOR
Intervention: Control non-therapeutic light
Number of subjects: 26
Study 27451942 — intervention group
Group type: EXPERIMENTAL
Intervention: ESAT6‐CFP10 (0.1, 0.5, 1 or 2 μg)
Number of subjects: 144
Study 27451942 — intervention group
Group type: COMPARATOR
Intervention: TB‐PPD
Number of subjects: 144
Study 27451942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 27451942 — intervention group
Group type: EXPERIMENTAL
Intervention: ESAT6‐CFP10
Number of subjects: 144
Study 24666527 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 72
Study 24666527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24666527 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs and Placebo
Number of subjects: 72
Study 22875822 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 704
Study 18503492 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weight‐bearing program
Number of subjects: 34
Study 18503492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 34
Study 17687925 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF inhibitors (pegaptanib, ranibizumab, bevacizumab)
Number of subjects: 0
Study 15158629 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental zinc (20 mg per day)
Number of subjects: 270
Study 11673813 — intervention group
Group type: EXPERIMENTAL
Intervention: Remune monotherapy (administered every 12 weeks)
Number of subjects: 223
Study 9040630 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium solution (30% dextrose in water; K+, 80 mEq/L; regular insulin, 50 units) given intravenously at 1 ml/kg per hour for 12 hours after aortic unclamping
Number of subjects: 30
Study 9040630 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium solution
Number of subjects: 30
Study 9040630 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (control)
Number of subjects: 30
Study 7702278 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin applied twice daily for 4 months
Number of subjects: 40
Study 7702278 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 months
Number of subjects: 40
Study 3584748 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75 micrograms, two doses)
Number of subjects: 10
Study 3584748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29405635 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice daily)
Number of subjects: 36
Study 29405635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29405635 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in healthy controls)
Number of subjects: 36
Study 27622565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography coronary angiography (DE-CTCA) at 45 keV
Number of subjects: 67
Study 27622565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography coronary angiography (DE-CTCA) at 65 keV
Number of subjects: 67
Study 27622565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography coronary angiography (DE-CTCA) at 85 keV
Number of subjects: 67
Study 27622565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography coronary angiography (DE-CTCA) at 45 keV with moderate calcification
Number of subjects: 67
Study 24618012 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (walking trial)
Number of subjects: 328
Study 23230756 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of autologous platelet-rich gel (APG)
Number of subjects: 117
Study 23230756 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 117
Study 20608820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous epinephrine administration
Number of subjects: 0
Study 20608820 — intervention group
Group type: COMPARATOR
Intervention: Standard epinephrine administration
Number of subjects: 0
Study 20608820 — intervention group
Group type: COMPARATOR
Intervention: Basic life support measures (chest compressions, defibrillation, postresuscitation care)
Number of subjects: 0
Study 18296456 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypocrisy intervention
Number of subjects: 0
Study 15973948 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate (Cerasorb)
Number of subjects: 20
Study 15973948 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone
Number of subjects: 20
Study 15973948 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both grafts
Number of subjects: 20
Study 12745511 — intervention group
Group type: EXPERIMENTAL
Intervention: 300mg bupropion SR + placebo patch
Number of subjects: 893
Study 12745511 — intervention group
Group type: EXPERIMENTAL
Intervention: 300mg bupropion SR + 21 mg/24-hr nicotine patch
Number of subjects: 893
Study 12745511 — intervention group
Group type: COMPARATOR
Intervention: 21 mg/24-hr nicotine patch
Number of subjects: 893
Study 12745511 — intervention group
Group type: COMPARATOR
Intervention: placebo tablet + placebo patch
Number of subjects: 893
Study 12745511 — intervention group
Group type: COMPARATOR
Intervention: placebo tablet + 21 mg/24-hr nicotine patch
Number of subjects: 893
Study 12504657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 10 mg/m2 on day 1 and continuous infusion of 5-fluorouracil (5-FU) 200 mg/m2 from days 1-26 in the first sequence (36 Gy over 4 weeks) and 5-FU 200 mg/m2 from days 1-17 in the second sequence (23.4 Gy over 17 days)
Number of subjects: 43
Study 12504657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 10 mg/m2 on day 1 and continuous infusion of 5-fluorouracil (5-FU) 200 mg/m2
Number of subjects: 43
Study 10701483 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan, titrated to 240 mg/day
Number of subjects: 14
Study 10701483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion, titrated to 450 mg/day
Number of subjects: 14
Study 7786531 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg twice daily
Number of subjects: 207
Study 7786531 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 207
Study 2190840 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver alloy and hydrogel-coated Foley catheter (SHC)
Number of subjects: 90
Study 2190840 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel-coated catheter (HC)
Number of subjects: 90
Study 2190840 — intervention group
Group type: COMPARATOR
Intervention: Non-coated catheter (NC)
Number of subjects: 90
Study 27977068 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist delivered interventions for low back pain (specific interventions not detailed in the abstract)
Number of subjects: 9328
Study 25496433 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal management training (GMT) for 21 hours
Number of subjects: 38
Study 25496433 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition (control)
Number of subjects: 38
Study 24386664 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 400 mg/day
Number of subjects: 24
Study 20392617 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 portion of fruit and vegetable (FV) daily for 8 weeks
Number of subjects: 117
Study 20392617 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 portions of fruit and vegetable (FV) daily for 8 weeks
Number of subjects: 117
Study 20392617 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 portions of fruit and vegetable (FV) daily for 8 weeks
Number of subjects: 117
Study 20392617 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased FV consumption
Number of subjects: 117
Study 20392617 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 portion of FV daily during run-in period)
Number of subjects: 117
Study 19346113 — intervention group
Group type: EXPERIMENTAL
Intervention: 25g/d of sesame (approximately 50mg/d of sesame lignan)
Number of subjects: 33